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Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and
usually lethal lung disorder of unknown etiology. The disease is charac-
terized by alveolar epithelial cell injury, formation of activated fibroblasts/
myofibroblasts foci and finally by the exaggerated accumulation of extracel-
lular matrix with the subsequent destruction of the lung architecture. The
long-term survival is distinctly poor, with only a 20 -- 30% survival 5 years after
the time of diagnosis. Actually, regardless of extensive research, no current
therapy has been shown to either reverse or stop the progression of
this disease.
Areas covered: The authors searched the Medline database from January
1990 to December 2010 using search terms ‘pulmonary fibrosis’, ‘fibrosing
alveolitis’ and ‘usual interstitial pneumonia’. Several subsets were included:
definition and epidemiology, risk factors, clinical behavior, pathogenesis
and therapy. For the section of IPF treatment, the authors examined all
relevant studies including randomized controlled trials, cohort studies, case-
control studies and cross-sectional studies. In this review, the authors describe
the current therapeutic approaches, the ongoing clinical trials and some
future options based on stem cells, lung bioengineering and microRNAs.
Expert opinion: The treatment of IPF represents one of the greatest chal-
lenges confronting respiratory medicine and, currently, there is no effective
therapeutic option for IPF. Perhaps some of the drugs that are under evalua-
tion in clinical trials will slow the decline of the pulmonary function tests or
hopefully stabilize some patients. Nonetheless, it appears clear that new
therapeutic approaches are urgently needed.
Keywords: IPF, lung bioengineering, microRNAs, stem cells, therapy
Expert Opin. Emerging Drugs [Early Online]
1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible lung
disorder of unknown etiology. The disease is characterized by alveolar epithelial
cell injury and activation, followed by migration/proliferation and activation of
mesenchymal cells with the formation of fibroblasts/myofibroblasts foci, and finally
by the exaggerated accumulation of extracellular matrix with the subsequent
destruction of the lung architecture. IPF is often (if not always) lethal, with a mor-
tality rate that exceeds that of many cancers, and currently it lacks from any effective
treatment. Importantly, IPF cannot be visualized as a simple scar, but rather a
dynamic and complex biopathological process. However, the underpinning patho-
genic mechanisms have not been elucidated, and only a detailed understanding of
these mechanisms will open new and effective therapeutic strategies. Based on our
current (although incomplete) understanding of the key pathogenic mechanisms
and given the poor response of IPF patients to a variety of existing drugs, a growing
number of clinical trials are going on aiming to target the cellular and molecular
events believed to perpetuate the fibrotic response.
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2. Background
The exact incidence and prevalence of this disease are
unknown, but it appears to be more common than previously
supposed. Using a large, geographically diverse US healthcare
claims database, Raghu et al. examined the prevalence and
annual incidence of IPF [1]. By a narrow case-finding criteria,
the prevalence ranged from 0.8 to 64.7/100,000 individuals
and the incidence from 0.4 to 7.1/100,000 people [1]. In the
UK, the incidence of IPF has increased progressively and has
more than doubled between 1990 and 2003 [2]. The rising
prevalence of IPF may be due to increased occurrence, recog-
nition and diagnosis, or increased reporting. Both the preva-
lence and the incidence of IPF augment markedly with age,
with prevalence exceeding 175 cases/100,000 individuals
who are > 75 years of age. Age also influences mortality and
the median survival time is significantly shorter in older indi-
viduals compared with younger ones [3]. Actually, IPF is con-
sidered an aging related disorder although the mechanisms
linking aging with the disease have not been elucidated [4].
Abnormal shortening of telomeres, oxidative stress and
epigenetic modifications may contribute to this association [4].
Mortality appears also to be increasing. Using data from the
National Center for Health Statistics (USA), Olson et al.
found that the age-adjusted mortality rate for IPF increased
28.4% in men (from 40.2 deaths/1,000,000 in 1992 to
61.9 deaths/1,000,000 in 2003) and 41.3% in women (from
39.0 deaths/1,000,000 in 1992 to 55.1 deaths/1,000,000 in
2003) [5].
Although IPF appears to be inexorably progressive and
lethal, the disease course is variable, with many patients
remaining stable or progressing slowly for long periods of
time while some others exhibit an accelerated course or expe-
rience acute exacerbations leading to respiratory failure and
death [6-9]. In addition, examination of high resolution CT
(HRCT) scan images has revealed that a number of patients
with IPF, primarily smoker males, may display the combina-
tion of emphysematous lesions and pulmonary fibrosis, which
has been called combined emphysema and pulmonary
fibrosis [10,11]. These patients develop severe pulmonary
hypertension and present decreased survival rate compared
with patients with IPF alone [11,12]. Also, patients with IPF
have higher risk to develop lung cancer. It is presently
unknown whether this increase is related to the abnormal
pathways upregulated in the disease or, as seems to be the
case in IPF combined with emphysema, this relationship is
not causal but directly associated to smoking [13].
2.1 Diagnosis
Specific diagnosis of IPF in patients having clinical and func-
tional features of an interstitial lung disease relies on HRCT
scanning or surgical lung biopsy showing a pattern of usual
interstitial pneumonia (UIP). Characteristics findings of
UIP by HRCT consist of bilateral, bibasilar and subpleural
distribution of irregular interlobular septal thickening and
honeycomb cysts often accompanied by traction bronchiecta-
sis and minimal ground glass attenuation (Figure 1) [14]. The
pathological pattern of UIP is characterized at low magni-
fication by a remarkable temporal and geographic heteroge-
neous appearance with alternating zones of normal or nearly
normal lung interspersed among widely scarred parenchyma
(Figure 2) [15]. There is architectural distortion provoked by
areas of honeycomb and fibrosis. Small clusters of spindle-
shaped fibroblasts and myofibroblasts within myxoid stroma
(fibroblast foci) are present in the background of collagen
deposition. These foci represent discrete, microscopic, subepi-
thelial zones of ongoing fibrogenesis and are characteristic
of UIP.
2.2 Pathogenic mechanisms
IPF is considered a complex disease probably arising from the
interplay between genetic and environmental factors. Heterozy-
gous mutations in surfactant protein (SP)-C and SFTPA2
genes, as well as in telomerase reverse transcriptase (TERT),
and TERC (RNA that contains a template for telomere repeat
addition) are probably responsible for about 15 -- 20% of all
familial interstitial pneumonias. In most families (80 -- 85%),
vertical transmission suggesting single autosomal dominant
mechanisms has been suggested, but the responsible genes
have not been identified [16]. It is likely that different genes
are responsible for disease across different families, contributing
to difficulty in their discovery. On the other hand, a number of
candidate genes have been evaluated in search for genetic fac-
tors in sporadic cases of IPF. Among others, polymorphisms
of genes encoding for cytokines (e.g., IL-1-a, TNF-a),
enzymes (a1-antitrypsin, ACE, MMP-1), profibrotic mole-
cules (TGF-b), and genes for SP-A and -B have been
studied [17]. Although some gene polymorphisms have been
reported showing increased frequencies in patients with spo-
radic IPF, none of these findings has been replicated in
subsequent studies. In addition, most of them have been per-
formed in relatively small cohorts of patients. Therefore, associ-
ation studies are inconclusive and at present there are no gene
polymorphisms consistently associated with the sporadic form
of the disease [17]. Genome-wide association studies that allow
a genome-wide screen for risk factors of disease by a case-
control association approach will probably open new windows
to identify underlying genetic factors responsible for the
development of sporadic IPF.
Several environmental exposures have been associated with
increased risk for IPF. To date, cigarette smoking is the most
consistent in both sporadic IPF and familial pulmonary fibro-
sis [18,19]. Also, several occupational factors, adjusted for age
and smoking, have been found significantly associated with
IPF, primarily metal and wood dust exposure [20,21].
2.3 Epithelial vs inflammation-driven fibrosis
The pathogenesis of IPF is largely unknown. For a long time,
the disease was considered as the result of a chronic
unresolved inflammatory reaction of the lung that was
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followed by fibroblast proliferation/activation and finally by
the exaggerated accumulation of extracellular matrix proteins.
However, in 2001 a new paradigm for pathogenesis, the
epithelial-driven fibrosis, was proposed [22]. According to
this hypothesis, alveolar epithelial cell microinjuries/apoptosis
provoke the migration, proliferation and the aberrant
activation of the neighboring epithelial cells, which in turn
secrete the mediators responsible for the expansion of
the fibroblasts/myofibroblasts population in the IPF lungs
(Figure 3) [23]. This proposed model caused controversy, and
several authors have debated that IPF is, as the other intersti-
tial lung diseases, an inflammation-driven fibrosis [24]. In sup-
port of the inflammation as playing a role in IPF, there is
some evidence suggesting that deregulated adaptive immune
mechanisms and subsequent inflammation may be implicated
either in the onset or in the progression of the disease in a sub-
group of IPF patients [25]. Thus for instance, marked downre-
gulation of CD28 on circulating CD4 T cells has been found
in some patients with IPF and appears to identify patients at
greatest risk for clinical deterioration [26]. Likewise, by gene
microarray analysis, in addition to genes associated with tissue
remodeling, an upregulation of genes related with chronic
inflammation and immune response, such as cytokines,
chemokines, complement and immunoglobulins, has been
reported suggesting an active ongoing chronic inflamma-
tion [27]. More recently, several interleukins, that is, IL-17A,
have been found to be increased in BAL fluids from IPF
patients, and appeared to be critical for the development of
experimental lung fibrosis [28]. Nevertheless, in a similar study
IL-17R-deficient animals or specific IL-17A neutralization
reduced the early inflammatory response but have no effect
on the fibrotic response induced by silica [29]. However, a
pathogenic role for inflammation cannot be excluded and
repeated injury may superimpose persistent inflammation
potentially enhancing disorderly tissue remodeling.
On the other hand, a growing body of evidence both in
experimental models and in the human disease supports the
epithelial hypothesis. First, several reports have demonstrated
the presence of focal areas of alveolar epithelial apoptosis
either in early or advanced stages of the disease [30-33] and, sec-
ond, numerous investigations have found that in this disease,
type II alveolar epithelial cells (AECIIs) synthesize virtually all
the mediators responsible of the migration, proliferation and
activation of the mesenchymal cells [23].
2.4 Alveolar epithelial cell death
The finding that SP-C mutations can cause epithelial cell
death and familial IPF, highlights the importance of the
AECIIs in the disease process [34,35]. The mutation results in
an aberrant pro-SP-C protein that cannot be correctly proc-
essed, resulting in protein misfolding, accumulation, induc-
tion of endoplasmic reticulum stress (ERS) and apoptosis of
the epithelial cells [36,37]. Recently, severe ERS response and
associated apoptosis were revealed in the AECIIs of patients
with sporadic IPF [38]. Furthermore, in another related
work, ERS and unfolded protein response activation were
found in AECIIs from patients with familial and sporadic
IPF, but interestingly, expression of herpesvirus proteins was
colocalized to this same cell population in the majority
of patients [39]. This was an important finding because
herpesviruses (primarily Epstein--Barr) are often found in
IM: 22
Figure 1. Usual interstitial pneumonia pattern on high
resolution CT in an IPF patient. There are bilateral subpleural
cysts in the lung bases (honeycombing), as well as reticulation
and traction bronchiectasis.
IPF: Idiopathic pulmonary fibrosis.
Figure 2. Usual interstitial pneumonia pattern on morphol-
ogy. Low-magnification view illustrates the patchwork
pattern of lung involvement with honeycombing alternating
with parenchymal scarring and normal lung.
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the epithelial cells of IPF lungs, and they are one of the sus-
pected risk factors for this disease [40]. Thus, viral replication
may be one of the causes for the induction of ERS and
repetitive injury to the alveolar epithelium in IPF.
Additional evidence in familial lung fibrosis also suggests
that mutations resulting in epithelial cell injury and apoptosis
may underlie the development of IPF. Heterozygous loss-of-
function mutations in the human telomerase genes have
been associated in close to 10% of familial IPF [41-43]. More
recently, the relationship between telomerase and epithelial
apoptosis was studied in sporadic IPF [44]. A significant
inverse association was found between low AECIIs telomerase
expression and apoptosis in apparent unaffected areas of IPF
lungs. Electron microscopy confirmed epithelial apoptosis,
alveolar collapse and initial fibroplasia. Taken together, these
works indicate that abnormal AECIIs telomerase/apoptosis
balance may reduce alveolar epithelial regenerative capacity,
thus contributing to the early lung remodeling.
2.5 Alveolar epithelial cell activation
However, despite apoptosis, there is an increase in the number
of alveolar/bronchiolar epithelial cells in the IPF lungs that
appears to be aberrantly activated. Actually, different studies
have demonstrated that they synthesized almost all, if not
all, the growth factors responsible for the migration and pro-
liferation of the resident lung fibroblasts and their differentia-
tion to myofibroblasts (e.g., platelet-derived growth factor
(PDGF), connective tissue growth factor (CTGF) and
TGF-b1) [23]. In addition, alveolar epithelial cells may chemo-
attract bone marrow-derived circulating progenitors that also
contribute to the expansion of the mesenchymal cells in the
IPF lungs. For example, a recent work has demonstrated
that in IPF, alveolar epithelial cells secrete CXCL12, a chemo-
kine that participates in the trafficking/homing of circulating
fibrocytes that express the receptor CXCR4 to the lungs [45].
Fibrocytes are a distinct subpopulation of leukocytes charac-
terized by the simultaneous expression of mesenchymal (colla-
gen type I, fibronectin), leukocyte (CD45) and hematopoietic
stem cell (CD34) markers [46,47]. Importantly, they are precur-
sors of myofibroblasts and may contribute to the expansion of
lung myofibroblasts after lung injury. Fibrocytes express a
variety of MMPs that may play a role in the process of fibro-
cyte migration throughout the basement membranes and the
interstitial matrix, and may also be implicated in fibrotic tis-
sue remodeling [48]. However, there is also some conflicting
evidence for bone-marrow derivation of myofibroblasts.
Thus, some studies performed primarily in mice indicate
that bone marrow-derived cells are unlikely to give rise to
a-SMA-expressing progeny [49].
Finally, alveolar epithelial cells may contribute to the
increase of lung fibroblasts/myofibroblasts through the epi-
thelial to mesenchymal transition (EMT). Epithelial cell plas-
ticity is a crucial and fascinating process in embryogenesis,
characterized by the functional phenotypic transition of
polarized epithelial cells into migratory, extracellular matrix
producing mesenchymal cells. In IPF, several studies have
Injury Apoptosis
Alveolar
epithelium
Herpes viruses, microaspiration, cigarette smoke, short telomeres, others
EMT
CXCL12
Fibrocytes Resident
fibroblasts
PDGF
Myofibroblast
focus
TGF-β TG
F-β
TGF-β
Dysregulation of developmental pathwaysProliferation,
migration,
activation
Extracellular matrix accumulation
Figure 3. Schematic view of the main mechanisms involved in the pathogenesis of idiopathic pulmonary fibrosis.
CXCL12: chemokine also known as stromal-derived factor-1; EMT: epithelial to mesenchymal transition; PDGF: platelet-derived growth factor.
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revealed the presence of lung cells showing epithelial and mes-
enchymal markers, thus putatively transiting from alveolar
epithelial cells to myofibroblasts [50,51]. TGF-b is the main
inducer of this process during development, carcinogenesis
and tissue fibrosis with different isoforms mediating various
effects depending on specific cellular context [52]. Interest-
ingly, viral infection seems to potentiate the effect of
TGF-b. In a recent work, it was shown that the latent mem-
brane protein 1 (LMP-1) from the Epstein--Barr virus sensi-
tizes alveolar epithelial cells to TGF-b1-induced EMT
response. Thus, at concentrations of TGF-b1 below the
threshold to cause EMT, LMP-1 induced dramatic pheno-
typic changes with concurrent loss of epithelial markers and
increased cellular motility [53]. However, the magnitude of
the contribution of EMT in tissue fibrosis is still under
some debate. Thus, for example, a recent study in kidney
fibrosis suggested that epithelial cells do not directly contrib-
ute to interstitial myofibroblast cells in vivo [54]. By using
either red fluorescent protein or b-galactosidase as fate
markers, no evidence that epithelial cells migrate outside of
the tubular basement membrane and differentiate into inter-
stitial myofibroblasts was found. Moreover, this study shows
that pericyte differentiation accounted for a large majority of
myofibroblasts at least in this model.
In a nutshell, strong evidence indicate that in IPF, activated
alveolar epithelial cells provoke the expansion of the fibro-
blasts and myofibroblasts that cluster in the fibroblastic foci
through the secretion of growth factors and chemokines that
induce the migration, proliferation and activation of local
lung fibroblasts as well as circulating progenitors, and also
directly transiting to myofibroblasts by the EMT process.
2.6 Alveolar epithelial cells and
extracellular proteases
In IPF, AECIIs also express several MMPs, for example,
MMP-1 and -7, although their function in this disease is still
unclear. These enzymes may be involved in extracellular
matrix remodeling, basement membrane disruption and/or
epithelial cell migration [55].
During the early stages of epithelial injury, a provisional
matrix composed of fibronectin and fibrinogen is formed, and
in order to facilitate the controlled alveolar re-epithelialization
this matrix should be degraded [56]. In this context, decreased
alveolar fibrinolysis provoking a local hypercoagulable state
appears to be implicated in the pathogenesis of IPF. Impor-
tantly, strong evidence supports that AECIIs are mainly
responsible of this pathological process. Thus, it has been dem-
onstrated in IPF that tissue factor, FVII, and FX are synthe-
sized by AECIIs and colocalize in the alveolar epithelium
overlying fibroblast foci, probably allowing the activation of
FX to FXa that in turn influences fibroblast functions,
that is, enhancing fibroblast-to-myofibroblast differentiation,
within the underlying fibrotic regions [57].
The molecular mechanisms responsible of the aberrant
behavior of the alveolar epithelial cells in IPF are unknown,
but recent evidence indicates that some developmental signal-
ing pathways are aberrantly activated or dysregulated [58].
Thus, for example, Wnt/b-catenin pathway is strongly upre-
gulated in the IPF lung epithelium and the Wnt1-inducible
signaling protein-1 (WISP1) is also increased in the AECIIs
of these patients [59,60]. Treatment of AECIIs with recombi-
nant WISP1 increases proliferation and induces EMT [60].
Abnormal recapitulation of embryologic pathways may also
affect fibroblast behavior. Thus, gremlin, an antagonist
of the bone morphogenetic protein (BMP)-4 during lung
development, is overexpressed in IPF lungs, primarily in
fibroblasts [61]. Moreover, TGF-b-induced EMT of lung
epithelial cells in culture is associated with induction of
gremlin mRNA expression [61].
3. Medical need
IPF patients have been treated for a long time with corti-
costeroids and in the last 15 years with a combination of
corticosteroids and immunosuppressive drugs [62]; however,
a systematic appraisal of the level of evidence available for
these treatments [63,64] showed that insufficient data support
this approach. Furthermore, although in the absence of a for-
mal demonstration of a lack of efficacy, clinical experience
confirms in daily practice that corticosteroids do not affect
the natural history of this disease.
Over the last years, despite the impressive increase in the
number of published studies on IPF pathogenesis (from
68 listed in PubMed for the first 10 months of 2000 to
245 listed for the same period of time in 2010), no useful
drug has reached most patients yet. As such, and in light of
the many practical and psychological obstacles posed by lung
transplantation, the medical need in IPF is one of the highest
among people affected with chronic respiratory disorders.
Overall, there is a consensus within the international med-
ical community that high-quality, prospective, controlled,
clinical trials of new therapies for IPF are urgently required,
although it is widely recognized that an effective treatment
for such a complex disease will require, analogous with cancer,
a combination of therapies targeting different multiple molec-
ular and cellular pathways. Additionally, there is a need for
targeting in future clinical trials end points of proven clinical
value, also acceptable to different regulatory agencies. As of
today, such clinical end points have been only partially iden-
tified and agreed upon that overall mortality does not appear
a feasible and realistic target for future trials. The end points
of such future studies will need to be chosen based on differ-
ent characteristics of various study populations, such as the
extent of disease and the presence of co-morbidities.
Finally, future studies and collaborative networks will
require addressing issues on non-pharmacological management
of IPF patients, including physical rehabilitation, psychological
aspects and end-of-life procedures. It is unfortunate that in
many institutions, terminally ill patients with IPF are
not managed accordingly to best care procedures, shared
Selman, Pardo, Richeldi & Cerri
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among different centers and focused on assuring adequate
comprehensive support to patients and their families.
4. Existing treatment
The evolving hypotheses on pathogenesis of IPF have changed
also varying over time the therapeutic approach to this devas-
tating disease. As mentioned, the classical view considered IPF
as a disease in which lung fibrosis was the consequence of a
chronic inflammation initiated by an unidentified insult and
ultimately leading to scarring. As such, corticosteroids have
been the initial mainstay of treatment, in association with
other immunosuppressive drugs, such as azathioprine. How-
ever, newly emerging concepts began to highlight the fact
that IPF is likely to originate as a consequence of an abnormal
wound healing process in which inflammation does not play a
central role. The injury to the alveolar epithelial cell layer,
through the secretion of several profibrotic mediators, is asso-
ciated with the formation of patchy fibroblast-myofibroblast
foci and deposition of extracellular matrix: in this scenario,
there is little rationale for any anti-inflammatory treatment.
As a consequence of this change of perspective on the patho-
genesis of IPF, over the last decade a number of basic research
studies led to translational studies exploring innovative thera-
peutic approaches, moving from an anti-inflammatory profile
to a more anti-fibrotic mechanism of action.
4.1 Corticosteroids
Corticosteroids are synthetic molecules derived from the
chemical structure of cortisol, the most important human
glucocorticoid hormone. These compounds have several bio-
logical effects, which can be grouped into two broad catego-
ries, metabolic (particularly on glucose metabolism) and
immunological effects. The action of corticosteroids on the
immune system results in suppression of both cellular and
humoral immune response and in a reduction on the levels
of pro-inflammatory molecules.
Results of some clinical trials exploring the efficacy of cor-
ticosteroids in the treatment of adults with IPF are summa-
rized in a recently updated Cochrane review [63]. Compared
to the previous version of the review published in 2003, the
current update further highlights the fact that in recent years
there has been a lack of interest in the use of corticosteroid
therapy alone in the treatment of IPF, as there was no new
clinical trial on this topic eligible for inclusion in a systematic
review and meta-analysis. Based on the results of this review
and on the current understanding of the pathogenesis of
IPF, there is no reasonable evidence supporting the use of
corticosteroids in this disease.
4.2 Azathioprine
Azathioprine is an anti-metabolite compound, orally available
and well absorbed by the gastrointestinal tract. The drug
blocks most T-cell functions, inhibits primary antibody
synthesis, and decreases the number of circulating monocytes
and granulocytes. Due to its immunomodulatory properties,
azathioprine was thought to be suitable for the treatment of
IPF, mostly given in association with corticosteroid therapy,
as recommended in the ATS/ERS Guidelines published
in 2000 [62]. Only one randomized clinical trial on the
efficacy of azathioprine in IPF has been published [65]. The
trial was a prospective, double-blind, randomized, placebo-
controlled study comparing the therapeutic effect of
combined prednisone/azathioprine with that of prednisone/
placebo in a very small group of IPF patients. Azathioprine
showed a small benefit on survival only when the analysis
was adjusted for age as a continuous variable at up to 9 years
of follow-up. With respect to the change in lung function
from baseline, although trends to improvement with azathio-
prine were observed, the difference between the treatment and
the control groups was not statistically significant.
4.3 N-acetylcysteine
N-acetylcysteine (NAC) acts as a precursor of the major anti-
oxidant glutathione. The rationale for the use of NAC in the
treatment of IPF is based on findings demonstrating that
there is an oxidant--antioxidant imbalance in this disease.
In addition, high-dose NAC has shown some immune-
modulatory properties in a different lung disease such as cystic
fibrosis [66]. Given its properties, NAC was evaluated in a
randomized clinical trial for the treatment of IPF in which
patients received either high-dose NAC or placebo in combi-
nation with prednisone and azathioprine [67]. While survival
was not affected by the treatment, the addition of NAC
showed a marginal positive effect in the change of DLCO
from baseline. NAC also was shown to slow the deterioration
of forced vital capacity (FVC) at 12 months, although the
difference in the absolute change of FVC from baseline
between the treatment and the control arm failed to reach a
conventional statistical significance. A subsequent analysis of
the data of patients who completed this trial showed that
lung function indices did not significantly change in patients
receiving NAC while deteriorated in those included in the
placebo arm [68]. Due to the lack of a true placebo arm in
this trial, it is difficult to argue whether the observed effect
is attributable only to the efficacy of NAC or is the result of
the interaction between drugs with different mechanisms of
action. Therefore, the National Institute of Health (NIH) is
currently sponsoring a new randomized clinical trial assessing
the efficacy of NAC alone compared to placebo.
4.4 Pirfenidone
Pirfenidone is an orally available small, synthetic non-peptide
molecule that is easily absorbed from the gastrointestinal tract
and that exhibits antifibrotic, anti-inflammatory and antioxi-
dant properties in several models. Pirfenidone suppresses
lung inflammation and fibrosis via inhibition of TGF-b-
induced collagen synthesis, inhibition of TNF-a production
and inhibition of the p-38g MAPK [69-72]. Promising results
from an open-label Phase II study supported the use of this
Emerging drugs for idiopathic pulmonary fibrosis
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drug in the treatment of IPF [73]. Subsequently, two random-
ized clinical trials assessing the efficacy of pirfenidone
compared to placebo in IPF patients have been already pub-
lished [74,75]. Two additional large multi-center randomized
clinical trials have been completed and data have been publicly
released to the FDA [76]. All four randomized clinical trials
have been included in a recently published Cochrane review
on non-steroid agents for IPF [64]. Based on the meta-analyses
presented in this systematic review, pirfenidone appears to
reduce the risk of disease progression by 30% and provide a
beneficial effect on the change of VC from baseline, compared
to placebo. Some limitations to this interpretation still apply,
mostly related to a certain degree of methodological heteroge-
neity between studies (i.e., the methods for reporting lung
function results), which did not allow including the results of
all four trials in one meta-analysis. However, these data look
encouraging and when considering the cumulative effect on
progression-free survival and the relatively safe profile of this
drug, pirfenidone appears a reasonable choice to treat IPF.
At present, pirfenidone has been already approved for clinical
use in IPF patients in Japan and India, and more recently it
received also the approval by the European Medicines Agency
for its use in Europe, while it has not been approved in the US.
4.5 IFN-g
IFN-g is an endogenously cytokine with antifibrotic, anti-
infective, antiproliferative and immunomodulatory proper-
ties. In several experimental models, IFN-g exhibited a
dose-dependent inhibition of fibroblast proliferation,
collagen-matrix deposition and collagen synthesis [77-79]. In
addition, exogenous IFN-g was shown to downregulate the
transcription of the TGF-b gene in a model of bleomycin-
induced fibrosis [80]. On these bases, IFN-g was thought to
be a potential drug for the treatment of IPF. First data on
the use of IFN-g 1b in IPF patients appeared in 1999 by
Ziesche et al. [81] and showed a significant beneficial effect
of this molecule in a very small single-center study. Two
large placebo-controlled randomized clinical trials were then
performed assessing the efficacy of IFN-g 1b in IPF
patients [82,83]. However, the results of these trials did not
confirm originally observations from Ziesche et al. Actually,
as demonstrated in recent meta-analyses, this drug does not
appear to be more effective than placebo neither on survival
nor on the change of lung function from baseline. Given these
data, there is no evidence to support any further use of IFN-g
1b alone in the treatment of IPF.
4.6 Imatinib
Imatinib mesilate is an orally available signal transduction
inhibitor, originally developed as an anticancer and approved
for the treatment of chronic myelogenous leukemia. Imatinib
is a specific tyrosine kinase inhibitor, with activity against
Bcr-Abl, PDGF receptors (PDGFR) and c-kit [84,85]. The
inhibitory activity on PDGFR suggested a potential activity
of the drug in IPF, through the suppression of the profibrotic
and proliferative activities mediated by PDGF. In fact, in pre-
clinical models imatinib was shown to be able to inhibit
bleomycin-induced lung fibrosis [86]. Daniels et al. have
recently published the results of a randomized clinical trial
on imatinib in patients with IPF [87]. This trial failed to dem-
onstrate a benefit for imatinib compared to placebo on any of
the outcomes selected for this study, and in particular did not
show a statistically significant difference between the treat-
ment and the control group in the progression-free survival
index or in the change of lung function from baseline.
4.7 Bosentan and other endothelin receptor
antagonists
Bosentan is an oral sulfonamide-based endothelin-A and -B
receptor antagonist, which has been developed for the treat-
ment of pulmonary arterial hypertension. Endothelin-1 is an
endogenous vasoconstrictor, which is involved in the patho-
genesis of pulmonary arterial hypertension. In addition to
the effects on vascular remodeling and vasoconstriction,
endothelin-1 has profibrotic activities through the modula-
tion of extracellular matrix deposition and turnover [88].
Data derived from a rat model of bleomycin-induced lung
fibrosis suggested that bosentan could be beneficial for the
treatment of IPF due to its ability to reduce collagen deposi-
tion in the lungs [89]. As such, a first randomized clinical trial
was designed in order to assess the efficacy of bosentan in
IPF [90]. The results of this trial did not show a benefit for
the drug compared to placebo on the change of the exercise
capacity. However, in a post hoc analysis a trend in favor of
bosentan was shown with respect to the time to death or
disease progression in a subgroup of patients diagnosed by
surgical lung biopsy. These findings supported the design of
a second large randomized clinical trial of bosentan in IPF.
The trial has been recently completed and data are not yet
available. However, the sponsor has released preliminary
results of this trial; the primary end point of reduction in
morbidity and mortality did not significantly differ between
treatment and placebo.
A selective endothelin-A receptor antagonist (ambrisentan)
was also under evaluation in the treatment of IPF patients,
with or without associated pulmonary hypertension, in a ran-
domized double-blind placebo-controlled trial. However, this
trial has been terminated due to lack of efficacy according to
an interim analysis of unblinded efficacy and safety data (see
Press Releases on the company website, www.gilead.com).
A further trial on this drug in patients with IPF and associated
pulmonary hypertension has been terminated as well (www.
clinicaltrials.gov). Full reports of these trials are awaited.
4.8 Etanercept
Etanercept is a soluble antagonist of TNF-a; the molecule
is recombinant human p75 TNF receptor and human
IgG1 Fc portion fusion protein produced in a mammalian
cell expression system and it was developed for the treatment
of rheumatoid arthritis and other inflammatory conditions.
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The interest for the use of this drug in IPF was based on the
observation of elevated levels of TNF-a in the lungs of ani-
mals in experimental models of lung fibrosis and in patients
with IPF. TNF-a is a cytokine that displays profibrotic and
inflammatory properties and the use of TNF-a antagonists
was shown to inhibit pulmonary inflammation and fibrosis
in an animal model of lung fibrosis. Given these observations,
TNF-a was thought to be a potential target in the treatment
of IPF and, therefore, a randomized placebo-controlled
clinical trial in IPF patients was designed [91]. However,
once again, promising preclinical data did not find confir-
mation in a randomized clinical trial: in fact, etanercept
did not significantly affect the main efficacy end points.
A nonsignificant reduction in disease progression was seen
in several physiologic, functional and quality of life end points
among subjects receiving etanercept [91].
4.9 BIBF 1120
Transmembrane receptor tyrosine kinases, a well-known
pharmacological target in oncology, recently became the focus
of clinical research in non-malignant disorders [92]. BIBF
1120 is a triple inhibitor of tyrosine kinase receptors, includ-
ing PDGFR, VEGFR and fibroblast growth factor receptors.
These receptors have been shown to be involved in lung fibro-
sis [93]. Treatment with BIBF 1120 was able to prevent the
development of lung fibrosis in a bleomycin rat model [94].
Preliminary results from the Phase II TOMORROW study
show that 12 months’ treatment with BIBF1120 resulted in
a clinically important reduction in the rate of decline in
lung function in patients with IPF, compared to placebo.
The 150 mg twice daily dose of BIBF1120 provided a 68%
reduction in the rate of decline of FVC compared with pla-
cebo. Secondary end points supported the efficacy of
BIBF1120. Only 2 (2.3%) patients in the 150 mg twice daily
BIBF1120 group suffered from an acute exacerbation of the
disease during the 12-month study period, compared with
12 (13.8%) patients in the placebo group; in addition,
patients taking 150 mg twice daily BIBF1120 reported less
deterioration in quality of life according to the St George’s
Respiratory Questionnaire compared with patients taking pla-
cebo. The total number of adverse events reported was similar
in the BIBF1120 and placebo groups. This molecule is now
entering Phase III in clinical development for the treatment
of IPF.
5. Current research goals and
scientific rationale
Because the absence of any reasonable effective drug for the
treatment of IPF, a growing number of clinical trials have
either been recently initiated or are in prospect (Table 1).
However, these new studies are approaching some putative
pathogenic mechanism by using a single drug approach.
Because it is likely that several fibrogenic mechanisms/
pathways are playing a role in the development and
progression of this disease, it is an easy prediction that no sin-
gle agent will effectively reverse or even halt the fibrotic
response in IPF. We need to search for multi-targeted
approaches that should be more effective than single agents.
Moreover, in the dynamic and complex process of fibrosis,
it is currently unknown which upregulated or downregulated
mediators are part of a pathogenic event and which might be
epiphenomena. Therefore, despite remarkable and unprece-
dented progress in our understanding of cellular and molecu-
lar mechanisms of fibrosis progression, the translation of this
knowledge into clinical practice through clinical trials has
been disappointingly unsuccessful until now. One of the
main problems is that a promising drug would have to show
efficacy in at least two mechanistically distinct fibrosis models,
with similar pathogenic mechanisms to IPF. Unfortunately,
there is no experimental model of lung fibrosis that accurately
mimics the disease, as we see it in human patients. In this con-
text, different models of lung fibrosis have been developed
over the years that mimic only few features of IPF. The
most common of them is induced by intratracheal instillation
or intravenous administration of bleomycin [95]. However,
even though the bleomycin animal model offers valuable
research tools for the elucidation of cells and mediators that
can contribute to fibrotic changes it has significant limita-
tions [95,96]. The main disadvantage of this experimental
model is that it does not recapitulate the cardinal characteris-
tics of IPF, primarily the progressive and irreversible nature of
the human disease. In general, the fibrotic response in mice is
self limiting and even reversible. Therefore, one of the most
critical hallmarks of human IPF is not present in animals,
which has to be considered when this model is used for
drug intervention studies [95].
Finally, although the final goal of clinical research should
ideally be to improve survival, this aim seems reasonably unre-
alistic to be obtained soon, mainly due to negative experience
of large previous trials and the prohibitive costs related to
large long-term trials dealing with rare diseases. However,
there is still some lack of general consensus on which would
be the best surrogate end point for mortality in IPF trials.
6. Competitive environment
For many years, the field of interstitial lung diseases was
completely neglected by pharmaceutical companies world-
wide. At the end of the 1990s, the initial report of an appar-
ently extraordinary effect of a biological drug (IFN-g) [81]
on clinical course of IPF patients fuelled the interest of phar-
maceutical companies for this neglected disease. Although
these initial findings have been disproved after two large trials
and huge financial investments, nonetheless, 20 years later,
the landscape of clinical trials in IPF has totally changed.
Now, not only many pharmaceutical private companies invest
money and efforts to design and complete the ‘perfect’ trial,
but also public health institutions (in particular the NIH in
the US, through the IPFnet organization) promote large
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randomized trials to address important clinical questions aris-
ing from previous studies or to evaluate the efficacy of poten-
tially relevant drugs, not supported by any company. Table 1
crystallizes the current landscape of clinical trials in IPF
worldwide: all phases of clinical research are now represented
and many, different geographical locations are present. On
one hand, this is certainly good news for both IPF patients
and for their physicians. On the other, however, competition
for patient recruitment among different trials is now emerg-
ing: for this reason, companies started recently to approach
areas of the world with a presumed high number of patients,
but traditionally not part of clinical research networks (at least
in this specific field), such as India and China: these ‘big play-
ers’, through excellent clinicians and top level health centers
will play an increasingly important role in allowing comple-
tion of large trials in a timely schedule. Ideally, it would be
advisable to have a global network of centers with expertise
in IPF so that it will be feasible to complete large trials enroll-
ing large numbers of patients with different racial background
and followed in different professional environments. This will
not only allow the completion of many trials (and, therefore,
the testing of many different working hypotheses) but will
also strength the collaboration within the IPF community at
a global level.
7. Potential development issues
7.1 Antioxidant drugs
As mentioned above, the potential for beneficial effects on
antioxidant therapies in IPF have been already explored by
the IFIGENIA study evaluating the efficacy of NAC [67].
This study did not include a true placebo arm and, therefore,
a further study on NAC is currently ongoing in the US
to assess whether NAC alone can have any effect on the
treatment of IPF patients.
However, new classes on antioxidant drugs are under eval-
uation for the treatment of IPF. In this context, NAPDH
oxidase-4 (NOX-4, an enzyme that catalyze the reduction of
O2 to reactive oxygen species) was found to be overexpressed
in IPF lungs, particularly in the thickened wall of pulmonary
arteries of IPF subjects [97,98]. In addition, NOX-4-dependent
generation of reactive oxygen species seems to be required for
TGF-b1-induced myofibroblast differentiation and extra-
cellular matrix production of IPF-derived mesenchymal
cells [97,99]. As such, a novel class of orally available NOX-4
inhibitors might have the potential for being tested in clinical
trials in IPF [100].
7.2 Targeting the extracellular matrix
Excessive extracellular matrix deposition is a key component
of pathologic changes in IPF and results in an altered
mechanic tension that supports the activation of pathogenic
signaling pathways and tissue remodeling, including further
activation of TGF-b1, thus establishing a vicious circle that
perpetuates the process of development of lung fibrosis [101].
As such, targeting the extracellular matrix could be a valuable
approach in order to interfere with the mechanisms of lung
fibrosis. Enzymes that modify the extracellular matrix include
lysyl oxidases, a family of five enzymes sharing a conserved
enzymatic domain with divergent N termini [102]. Lysyl oxi-
dase (LOX) and LOXL2 promote crosslinking of fibrillar col-
lagen, a major component of extracellular matrix in lung
fibrosis. LOXL2 expression has been described in tumors
and in liver fibrosis, with a possible role in promoting inva-
sion. LOXL2 also appears to be overexpressed in lung tissue
of patients with IPF, particularly in association with activated
fibroblasts, reactive pneumocytes and vasculature in fibroblas-
tic foci [103]. Moreover, treatment with a LOXL2 allosteric
inhibitory mAb in the bleomycin-induced model of pulmo-
nary fibrosis resulted in significant reduction of lung fibrosis,
decreased number of activated fibroblasts in the lungs and
significant reduction of profibrotic mediators, including
TGF-b1 [103].
Certainly, this mechanism provides a new appealing way of
targeting lung fibrosis and, interestingly enough, the fact that
this same pathway appears to be involved also in the process of
tumor invasion by solid tumors could establish a further con-
nection between fibrosis and cancer, thus, corroborating the
recent thinking that effective treatment of IPF might take
advantage from lessons learned in the oncology field [92].
7.2.1 Is there a role for targeting the
coagulation cascade?
Accumulating evidence in recent years has provided a ratio-
nale for a beneficial role of targeting the coagulation cascade
in the treatment of IPF. From a clinical point of view, there
is only one unblinded study that addresses the effect of antico-
agulant therapy in IPF patients. The study showed a signifi-
cant reduction in overall mortality in the group of patients
receiving prednisolone plus anticoagulation compared to the
prednisolone alone group [104].
What are the mechanisms that would explain an implica-
tion of coagulation cascade in lung fibrosis? Several pieces of
evidence have actually gained recent interest in supporting a
potential role of the coagulation pathways in the fibropro-
liferative response to lung injury. First of all, the coagulation
cascade appears to be activated in several fibrotic lung diseases
by means of elevated expression of tissue factor in the
lung [105,106] and increased levels of thrombin in the bron-
choalveolar lavage fluid of patients with fibrotic lung dis-
ease [106]. Moreover, Scotton et al. have provided evidence
that the upstream coagulation zymogen, Factor X, is locally
produced and activated in the intra-alveolar compartment of
patients with IPF and in the bleomycin model [57]. In parallel,
anticoagulant protein C pathway was shown to be deficient
in IPF lungs. On the other hand, anticoagulants are highly
effective in attenuating fibrosis in experimental animal models
either prophylactically [57,107] or therapeutically [108].
Another mechanism that is related to the coagulation
cascade and is thought to be involved in the process of fibrosis
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involves a direct receptor-mediated cellular effects elicited by
activation of the major high-affinity thrombin receptor,
proteinase-activated receptor (PAR)-1 [56]. Numerous cell
types, including fibroblasts, epithelial cells and macrophages,
express PAR-1. The activation of this receptor leads to the
release of pro-inflammatory and profibrotic mediators such
as PDGF and CTGF by fibroblasts [109,110]. In addition, it
promotes the integrin-dependent TGF-b1 activation [111]
and thus contributes to the differentiation of fibroblasts into
myofibroblasts. Furthermore, studies in the PAR-1 knockout
mice have shown that these animals are protected from
bleomycin-induced lung fibrosis, with an associated reduction
in profibrotic mediators and chemokines [112]. Hopefully, this
evidence will be soon translated into clinical application as
several antagonists of PAR-1 are being already developed as
drug compounds in the setting of cardiovascular disease.
Few trials in this field have been already completed, although
results are still awaited. A Phase II trial in patients undergoing
non-urgent percutaneous coronary intervention has shown
good tolerability and no increased risk of bleeding even
when SCH 530348, an oral platelet protease-activated
receptor-1 antagonist, was administered with aspirin or clopi-
dogrel [113]. The potential advantages of PAR-1 antagonists
compared to anticoagulant therapy are potentially elated
to a reduced risk of bleeding complication as these novel
drugs would compete with receptor-mediated cellular effects
of coagulation proteinases rather than interfering with the
coagulation cascade and fibrin formation.
7.3 Is it possible to inhibit fibrocytes trafficking and
differentiation, and the process of epithelial to
mesenchymal transition?
As mentioned, there are at least three potential sources for the
increase of fibroblasts/myofibroblasts in the IPF lungs: the
expansion of resident lung fibroblasts, the recruitment
and differentiation of circulating mesenchymal precursors
(fibrocytes) and the process of EMT.
In this context, a growing body of evidence suggests that
some molecules can inhibit fibrocytes differentiation. For
example, serum amyloid P (SAP), a naturally circulating solu-
ble pattern recognition receptor, can directly inhibit mono-
cytes from differentiating into fibrocytes [114]. Moreover,
injections of SAP in rats or mice reduce bleomycin-
induced lung fibrosis [115]. Likewise, other putative regulators
of fibrocytes include IFN-a2b, adenosine A2A receptor and
cysteinyl leukotriene receptor 1 [116-118]. Deletion or blockade
of adenosine A2A receptor inhibited the recruitment of
fibrocytes in bleomycin-treated mouse skin [117]. Likewise,
fewer fibrocytes are noticed in the lungs of fluorescein
isothiocyanate-treated 5-lipoxygenase-deficient mice com-
pared with wild-type mice [118]. On the other hand, it is also
possible to decrease the traffic of circulating fibrocytes to
the lungs blocking the effect of the chemokines involved in
their recruitment. Thus, it was demonstrated that treatment
of bleomycin-exposed animals with specific neutralizing
anti-CXCL12 antibodies inhibited the intrapulmonary
recruitment of circulating fibrocytes and attenuated lung
fibrosis [119].
On the other hand, as previously mentioned, epithelial cells
may respond to microenvironmental signals by undergoing
EMT that also promotes the expansion of the myofibroblast
population. In this context, targeting key signaling pathways
to attenuate this process may have a profound effect on
fibrogenesis and, currently, several studies are evolving in
the area of cancer [120]. Thus, a recent report has shown that
sorafenib (Nexavar; Bayer HealthCare Pharmaceuticals,
Inc.), a VEGFR and PDGFR-b inhibitor with activity against
RAF kinase, exerts a potent inhibitory activity against the
EMT by inhibiting MAPK signaling and SNAI1 expression
in hepatocellular carcinoma cells [121]. Some microRNAs
(miRNAs) could be other targets by which to block EMT
(see below).
7.4 Is it possible to improve epithelial regeneration?
Three members of the fibroblast growth factor (FGF) family,
keratinocyte growth factor (KGF), FGF-10 and FGF-1, as
well as the hepatocyte growth factor (HGF), may play a
role for the appropriate epithelial repair in IPF lungs. For
example, it has been shown that transient overexpression of
gremlin, a BMP antagonist, induces alveolar epithelial apo-
ptosis and lung fibrosis that is reverted after the selective
upregulation of FGF10 [122]. Likewise, it has been demon-
strated that FGF-1 displays antifibrotic functions downregu-
lating collagen expression and antagonizing some profibrotic
effects of TGF-b [123,124]. More recently, it was reported
that FGF-1 reverts TGF-b1-induced EMT in alveolar epithe-
lial cells throughout MEK--ERK pathway inducing the
dephosphorylation of Smad2 [125].
Also, experimental studies have shown that human HGF
gene transfer increases endogenous lung HGF preventing
AECIIs from further apoptosis and resulting in reduced fibro-
sis after bleomycin injury [126]. Likewise, intratracheal instilla-
tion or intravenous administration of KGF protects the lungs
against several experimental injuries [127]. More recently, it
was shown that bone marrow stem cells expressing KGF
via an inducible lentivirus attenuates bleomycin-induced
pulmonary fibrosis [128]. In addition, KGF-gene transduc-
tion by intratracheal administration of KGF-expressing
adenovirus vector was shown to result in decreased fibrosis
in the bleomycin model in mice and reduced mortality.
KGF-associated effects included alveolar epithelial cell prolif-
eration, suppression of TGF-b1 production and increased SP
secretion [129].
Whether these approaches will have a role in the treatment
of IPF is at the present largely unclear. However, it has to be
mentioned that at least one molecule of the FGF family has
reached the clinical use for epithelial repair in other fields.
In fact, human recombinant KGF (palifermin, Kepivance)
is marketed in some countries for the prevention of severe
oral mucositis in patients with hematologic malignancies
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receiving myelotoxic therapy requiring hematopoietic stem
cell support [130-132].
7.5 Interfering with developmental pathways
In a recent report, using the bleomycin-induced model of
pulmonary fibrosis in transgenic BAT-gal mice, it was dem-
onstrated that, as reported in IPF, aberrant activation of
Wnt signaling in the lungs was induced after injury [133].
Bleomycin-induced fibrosis and the overexpression of profi-
brotic genes were significantly reduced by the specific inhibi-
tor of Wnt/b-catenin/CBP-driven transcription, ICG-001.
The inhibitor decreased epithelial cell apoptosis and EMT
both in vivo and in vitro. Amelioration of fibrosis, together
with improved survival, following both concurrent and late
administration of ICG-001, provided preliminary evidence
for selective blockade of Wnt/b-catenin-CBP-dependent
transcription signaling as a potential therapeutic strategy for
human fibrotic lung diseases.
7.6 Embryonic stem cells
Because the current strategies for IPF treatment have been
limited and unsuccessful, novel therapeutic strategies are
urgently needed. Lung transplantation is usually the only
option for patients with irreversible structural lung damage
including those with IPF; however, organ availability lags
far behind demand. Thus, given the scarcity of donors
and the aging and disease complications of IPF patients,
transplantation is indicated only in carefully selected
patients. In addition, many of them die in the waiting
list. The main problem after injury is to re-establish the
integrity and functional organization of the epithelial layer,
and of the alveolar-capillary units. Probably this occurs dur-
ing normal repair by the migration and spreading of nearby
and newly recruited circulating progenitor cells that prolif-
erate and undergo phenotypic differentiation to cover the
denuded surfaces [134]. In this context, a number of studies
performed in the last decade have suggested that both
embryonic and adult tissue-derived stem cells may play a
role in the regeneration and repair of diseased adult organs
including the lungs [135].
Embryonic stem cells (ESCs) are self-renewing pluripotent
cells which can be induced to differentiate into a wide range of
different cell types [136]. Thus, at least theoretically, alveolar
type II epithelial cells derived from ESCs may be used
therapeutically to treat fibrotic disorders that show lost of
epithelial integrity and abnormalities in re-epithelialization.
However, an important goal in this area is to obtain pure
AECIIs from embryonic cells. This objective was recently
achieved [137], and it was also demonstrated that lung progen-
itor epithelial cells derived from human ESCs can indeed be
transplanted into damaged alveoli of mice and that these
cells are able to reverse bleomycin-induced pathological
changes [138]. Thus, while non-treated mice exposed to
bleomycin showed large extent of interstitial thickening by
extensive interstitial inflammation and fibrosis, with the
formation of cystic air spaces, ESC-AECIIs transplanted
mice exhibited a greatly reduced damage as evidenced by
only a few isolated, small areas of injured tissue surrounded
by much larger areas of normal alveolar structure [138].
Whether this effect resulted from structural engraftment of
the administered cells or reflected some kind of paracrine
effect of the ESC-derived AECIIs is not yet clear. Interest-
ingly, the therapeutic benefits provided by the transplan-
tation of these cells were long-term and without the
development of teratomas [138]. This is an important obser-
vation because one of the potential risks with the use of
ESCs or induced pluripotent stem cells is the induction
of malignancies.
7.7 Induced-pluripotent stem cells
Recently, a novel dedifferentiation technology that allows the
generation of induced- pluripotent stem (iPS) cells has been
developed. The expression of four transcription factors
Oct4, Sox2, c-myc and Klf4 is able to induce epigenetic
reprogramming of a somatic genome to an embryonic plurip-
otent state [139,140]. Patient-adapted iPS cells remove the major
problem of donor immune rejection for clinical applications
and also mitigate ethical concerns associated with the use of
human ESCs [141]. However, the use of retrovirus-transduced
oncogenes represents a serious barrier to the eventual use of
reprogrammed cells for therapeutic application.
In addition, although several methods have been developed
for generating iPS cells free of reprogramming transgenes, a
sufficiently efficient reprogramming system is still required
in order to achieve the widespread derivation of disease-
specific iPS from humans with different disorders. In this con-
text, Somers et al. [142] reported the use of a humanized
version of a single lentiviral ‘stem cell cassette’ vector in order
to accomplish efficient reprogramming of normal or diseased
skin fibroblasts obtained from humans of virtually any age.
The vast majority of clones obtained with this method con-
tained a single integrated vector copy which can be excised
to obtain human iPS cells free of integrated transgenes. The
authors applied this strategy to generate numerous lung
disease-specific iPS cell lines from individuals with a variety
of diseases affecting the epithelial, endothelial or interstitial
compartments of the lung, including cystic fibrosis, a-1 anti-
trypsin deficiency-related emphysema and scleroderma. This
work indicates that it is possible to reprogram human somatic
cells with high efficiency by using a single polycistronic excis-
able lentivirus expressing the four transcription factors, Oct4,
Klf4, Sox2 and c-myc. Additionally, the authors demon-
strated that human iPSC generated with this approach have
the ability to robustly differentiate into definitive endoderm
in vitro, the developmental precursor tissue of lung epithelia.
However, several problems should be solved, for example,
their capacity for tumorigenesis in vivo, in order to determine
whether iPS cells will have a role in the treatment of chronic-
degenerative diseases, including IPF, as vehicles for gene or
cell therapies.
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7.8 Adult mesenchymal stem cells
Mesenchymal stem cells (MSCs) are multipotent cells able to
differentiate into a range of cell types that are being tested for
their regenerative potential in several diseases. In a pioneer
work, Ortiz et al. [143] demonstrated that MSCs engraft in
the lungs of normal mice at low levels, but engraftment
increases significantly in response to bleomycin-induced
lung damage. In the injured lungs, engrafted donor cells
adopted an epithelium-like morphology. In addition, it was
found that early but not late administration of MSCs amelio-
rated the fibrotic response observed in the lungs of bleomycin-
treated mice. In another study, it was indicated that bone
marrow-derived MSCs seem to decrease bleomycin-induced
lung injury and fibrosis not only by supplying stem cells to
the lung but also because they produce growth factors, such
as GM-CSF and G-CSF that may mobilize endogenous
stem cells from bone marrow pools to the lungs [144]. Interest-
ingly, in this study, donor-derived cells in the lungs showed
phenotypic characteristics of several lung cell types, includ-
ing type I and II alveolar epithelial cells, fibroblasts and
endothelial cells.
More recently, MSCs derived from the Wharton’s jelly of
human umbilical cords were used to prevent bleomycin-
induced fibrosis [145]. These cells have the advantage of ready
availability and that do not require invasive bone marrow
biopsies. As previously shown, the pneumonitis induced by
bleomycin was strongly attenuated by MSC treatment. Inter-
estingly, MSCs were detected in both the fibrotic and nonfi-
brotic areas of the bleomycin-injured lungs at 14 days but
not at 28 days after injection. The antifibrotic effect appears
to be related to downregulation of lung cytokines and
TIMP expression. Likewise, in another recent study it was
shown that systemic transfer of MSCs effectively reduced
the bleomycin-induced lung injury and fibrosis through the
downregulation of NO metabolites, and pro-inflammatory
and angiogenic cytokines [146].
In general, the results obtained with adult MSCs are prom-
ising. However, a number of yet unresolved problems persist.
Several studies using different technical approaches have
shown virtually no detectable reconstitution of lung alveolar
epithelial cells by bone marrow derived cells [147,148]. Never-
theless, chronic or progressive lung injury may result in
more substantial engraftment of stem cells. After systemic
adult stem cells administration, many of them may initially
localize in lungs as the first major capillary bed encountered,
and lung damage may result in increased retention of these
cells. The phenotypic instability related to plasticity raises
concerns the outcome of transplanted cells that may undergo
unwanted and deleterious differentiation after implantation/
engraftment at specific sites [149]. The transformation poten-
tial is also a major concern [150,151]. In addition, it is important
to consider that the mechanisms by which stem cells
acquire one or another phenotype(s) in the lung remain
poorly understood. Moreover, mechanisms responsible for
its therapeutic role are not well understood, and may involve
plasticity or, as much evidence indicates, paracrine and immu-
nomodulatory activities without significant engraftment and
differentiation [151].
7.9 Bioengineering the lung
In the last years, several studies have tried to bioengineer
lung-like tissues using synthetic (such as polymers, polygly-
colic acid) or natural (e.g., collagen, basement membrane
components) scaffolds on which to grow lung (primarily
epithelial) cells, but these scarcely replicate the complexity
of the lungs. In a recent paper, it was shown that mouse
lungs can successfully be decellularized while maintaining
the extracellular matrix in the correct geospatial branching
pattern even after prolonged ventilation [152]. Moreover,
fetal lung cells were successfully infused and cultured in
decellularized, ventilated lungs. This work demonstrated
that decellularized whole lungs can be used as natural scaf-
folds in a bioreactor system, supporting the fact that the
natural matrix of the lung is an excellent scaffold from
which to rebuild a lung.
In the same line of thought, an outstanding work dealing
with the construction of a functional tissue-engineered lung,
using rat as a model system, was also recently published [153].
The authors decellularized native lung tissue in order to
remove all immunogenic cellular constituents, showing
that after this procedure, the tissue retained its alveolar
micro-architecture, its ability to function as a barrier to par-
ticulates and its tissue mechanics. The acellular lung matrix
was repopulated with mixed populations of neonatal lung
epithelial cells, which resulted in regional-specific epithelial
seeding in correct anatomic locations. Likewise, microvascu-
lar lung endothelial cells injected into the pulmonary artery
of acellular scaffolds were able to adhere throughout the
scaffold vasculature. To enhance the survival and differenti-
ation of lung epithelium, the matrix was cultured in a bio-
reactor designed to mimic certain features of the fetal lung
environment, including vascular perfusion and liquid venti-
lation. Finally, to determine whether engineered rodent
lungs were implantable and functional for gas exchange,
orthotopic left lung transplantation was performed in four
rats. All engineered lungs became perfused with blood
over a period of seconds to minutes, and blood gas analysis
revealed that the tissue-engineered lungs were effective
in exchanging oxygen and carbon dioxide. Although
yet far from human tissue bioengineering, these results
are encouraging.
7.10 microRNAs
miRNAs are small (17 -- 25 nucleotides) non-coding, naturally
occurring RNAs that comprise a new class of transcriptional
gene regulators. miRNA guide post-transcriptional gene
silencing by either translational repression or by degradation.
Dysregulation of miRNAs is known to be involved in a
variety of pathological processes, and three recent papers
have suggested a possible role in the pathogenesis of IPF.
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Pandit et al. [154] performed miRNA microarrays in 10 IPF
and 10 control lungs and found 46 miRNAs differentially
expressed. Among the significantly decreased miRNAs in
IPF lungs were let-7d, miR-26 and several members of the
miR-30 family. Decreased let-7d was primarily localized in
epithelial cells and directly inhibited by TGF-b. Importantly,
the inhibition of let-7d in vitro caused EMT-like changes in
lung epithelial cells, while in vivo provoked spontaneous
alveolar septal thickening in the mouse lungs.
Likewise, it was reported that lungs of mice with
bleomycin-induced fibrosis as well as IPF lungs show an upre-
gulation of miR-21 [155]. Increased miR-21 expression was
primarily localized to myofibroblasts. Increasing miR-21
levels promoted, whereas knocking down miR-21 attenuated,
the pro-fibrogenic activity of TGF-b1 in fibroblasts, and
miR-21 antisense probes attenuated bleomycin-induced lung
fibrosis.
More recently, in a large scale screening for miRNAs
potentially involved in bleomycin-induced fibrosis, it was
found that the expression of miR-29, which is expressed
by mesenchymal cells, is significantly reduced in fibrotic
lungs [156]. miR-29 levels inversely correlated with the expres-
sion of several profibrotic target genes and with the severity
of the fibrosis. In fibroblasts, miR-29 was suppressed by
TGFb1 and many fibrosis-associated genes upregulated by
TGFb1 were derepressed by miR-29 knockdown.
Taken together, these studies suggest that, at least in part,
the effects of TGF-b, an essential pathological mediator of
lung fibrosis, may be related to its capacity to decrease the
expression of ‘antifibrogenic’ miRNAs in alveolar epithelial
cells (let-7d) or fibroblasts (miR-29), while may increase
the expression of a ‘profibrogenic’ miRNA (miR-21) in
lung fibroblasts.
The putative therapeutic application of miRNAs involves
two strategies [157]. One approach is directed to inhibit upre-
gulated, potentially pathogenic, miRNAs by using miRNA
antagonists, such as anti-miRs, locked-nucleic acids or antago-
miRs. These miRNA antagonists are oligonucleotides with
sequences complementary to the endogenous miRNA. The
second strategy, miRNA replacement, involves the reintro-
duction of a downregulated miRNA attempting to restore a
loss of function [157].
Some advances have been made in cancer treatment. For
example, let-7 expression is reduced in a subset of NSCLC
patients, and this reduction is correlated with poor prognosis.
Using both inducible and constitutive expression systems,
substantial tumor suppression by let-7 g that function as a
tumor suppressor both in xenografts and in a mouse lung
tumor model has been found [158]. These findings make clin-
ically relevant predictions related to the use of let-7-based
therapeutic agents in this type of cancer.
Another miRNA that is also suppressed in human NSCLC
tissues is miR-34a, and recent data provide evidence for the
safe and effective therapeutic delivery of a synthetic miR-34a
mimic [159]. It was demonstrated that miR-34a inhibits the
growth of cultured lung cancer cells and that intratumoral
delivery of formulated miR-34a in a lipid-based vehicle blocks
lung tumor growth in mice.
In lung fibrosis, it was shown that administration of miR-21
antisense probes attenuated the severity of bleomycin-
induced lung fibrosis in mice, even when treatment was started
5 -- 7 days after initiation of the lung injury, suggesting the
possibility of using miRNA therapeutics [155].
Certainly, many studies are needed to address long-term
efficacy and safety of miRNA therapy in humans but the cur-
rent evidence supports the development of this new class
of therapeutics.
8. Expert opinion
The treatment of IPF represents one of the greatest challenges
confronting respiratory medicine and, currently, there is no
effective therapeutic option for IPF. Perhaps some of the
drugs that are under evaluation in clinical trials will slow
the decline of the pulmonary function tests or hopefully
stabilize some patients. Nonetheless, it appears clear that
new therapeutic approaches are urgently needed.
A growing list of mediators and pathways putatively
involved in the pathogenesis of IPF could be exploited in
the development of antifibrotic drugs. However, although
extensive progress has been made in identifying the pathogenic
mechanisms implicated in this disease, many unanswered
questions remain. In this context, the lack of efficient
therapeutic options and design of more effective drugs is at
least partially due to the fact that the underlying mechanisms
leading to lung fibrosis are not completely understood.
In addition, the design of antifibrotic strategies for clinical
purposes entails enormous obstacles. One of the most difficult
problems that we face is to find the most appropriate clinical
end points: ideally, the best are survival and quality of life. An
effective drug should, therefore, significantly decrease mortal-
ity, improving at the same time the quality of life. However,
this scenario implies long-term large randomized clinical trials
with several hundred or even thousands of well-characterized
patients. Unfortunately, noninvasive methods, such as serum
biomarkers or better imaging or respiratory functional techni-
ques that can quickly quantify changes in the natural history
of the disease, for example, rapid versus slowly progressive
disease are scanty. This is an important issue because IPF is
a heterogeneous disease showing a varied clinical behavior
with some patients evolving slowly while others progress
rapidly and die in few months or years after the beginning
of symptoms.
Given the complexity of this disease, it would be expected
that the best therapeutic approach should include several
drugs that target epithelial cells and fibroblasts and several sig-
naling pathways. Disappointingly, however, a recent trial with
imatinib that potentially targets several signaling pathways by
inhibiting transmembrane receptor tyrosine kinases showed
no effect.
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Is there a promissory future for the treatment of IPF? Yes,
but not in the short time. Regenerative therapy using stem
cells, lung bioengineering to obtain healthy organs for trans-
plant or the utilization of nucleic acid-based therapeutic mol-
ecules (e.g., miRNA) can open solid perspectives and it is
hoped that combining these and other modalities will translate
into improved clinical outcomes. Certainly, the accurate scien-
tific appraisal of potential risks and limitations of these thera-
pies to generate strategies for overcoming them and providing
a safe and efficient clinical application will be necessary.
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